Introduction
Methods
Results
Characteristic | Telavancin (n = 89) | Vancomycin (n = 105) |
---|---|---|
Age (years) | ||
Mean (SD) | 61.7 (18.6) | 67.0 (15.4) |
Median (IQR) | 67.0 (50.0, 75.0) | 72.0 (60.0, 77.0) |
Age distribution, n (%) | ||
< 65 years | 40 (44.9) | 37 (35.2) |
≥ 65 years | 49 (55.1) | 68 (64.8) |
Sex, n (%) | ||
Male | 47 (52.8) | 61 (58.1) |
Female | 42 (47.2) | 44 (41.9) |
Ethnicity, n (%) | ||
Hispanic or latino | 20 (22.5) | 21 (20.0) |
Not hispanic or latino | 69 (77.5) | 84 (80.0) |
Race, n (%) | ||
American Indian or Alaska Native | 5 (5.6) | 3 (2.9) |
Asian | 17 (19.1) | 20 (19.0) |
Black or African American | 3 (3.4) | 4 (3.8) |
White | 64 (71.9) | 78 (74.3) |
BMI (kg/m2) | ||
Mean (SD) | 26.2 (5.84) | 25.5 (6.03) |
Median (IQR) | 25.4 (22.2, 29.1) | 23.8 (21.6, 28.3) |
APACHE II Score (mean, SD) | ||
Mean (SD) | 15.2 (6.09) | 15.5 (6.95) |
Median (IQR) | 15.0 (11.0, 19.0) | 14.0 (11.0, 20.0) |
CrCl (mL/min) | ||
Mean (SD) | 89.7 (62.2) | 76.0 (57.4) |
Median (IQR) | 68.5 (43.0, 118.5) | 63.6 (40.7, 91.7) |
VAP, n (%) | ||
Yes | 26 (29.2) | 21 (20.0) |
No | 63 (70.8) | 84 (80.0) |
MRSA, n (%) | ||
Yes | 61 (68.5) | 88 (83.8) |
No | 28 (31.5) | 17 (16.2) |
MSSA, n (%) | ||
Yes | 28 (31.5) | 17 (16.2) |
No | 61 (68.5) | 88 (83.8) |
Common comorbidities (≥ 20%), n (%) | ||
Hypertension | 55 (61.8) | 67 (63.8) |
Anemia | 39 (43.8) | 34 (32.4) |
Diabetes mellitus | 35 (39.3) | 34 (32.4) |
Atrial fibrillation | 22 (24.7) | 25 (23.8) |
Cardiac failure, congestive | 22 (24.7) | 14 (13.3) |
Chronic obstructive airways disease | 21 (23.6) | 31 (29.5) |
Renal comorbidities | ||
Renal failure, acute | 9 (10.1) | 12 (11.4) |
Renal failure, chronic | 9 (10.1) | 9 (8.6) |
Renal insufficiency | 4 (4.5) | 5 (4.8) |
Renal impairment | 1 (1.1) | 0 |
Blood creatinine increased | 1 (1.1) | 0 |